This novel mechanism of action, in contrast to classical CXCR4 antagonists, allows to control efficiently the production of type 1 interferons by plasmacytoid dendritic cells (pDC) known to play a central and upstream role in the inflammatory cascade.
First chemical series generation, and proof of concept in several auto-immune disease animal models of auto-immune diseases have opened the door to the discovery of a brand-new class of drugs to be developed by Ermium.
Ability to potently downmodulate type I interferons and other key inflammatory cytokines.
Modulation of a panel of key immune cells expressing CXCR4, including pDC.
A key property for drug candidates aimed to be used in chronic diseases.
Ermium Therapeutics © 2023 All Rights Reserved
Design by Cédric Adam
